Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

NIH

Sponsor class

Conditions

Metastatic Solid Tumors
Treatment-Refractory Cancers

Interventions

DRUG: rhIL-15
DRUG: Ipilimumab
DRUG: Nivolumab
PROCEDURE: Tumor biopsies
DIAGNOSTIC_TEST: EKG
DIAGNOSTIC_TEST: ECHO
DIAGNOSTIC_TEST: CT Scan

Sponsor

National Cancer Institute (NCI)